Degli Pharmaceutical-B (06996) announced, the company's first new drug of its kind, celinisol tablets (trade name: Sivio
Zhitong Finance App News, Deqi Pharmaceutical-B (06996) announced, the company's first new drug of its kind, celinisol tablets (trade name: Sivio) has been successfully included in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2023)”. The scope of medical insurance payments is: “Limited to adult patients with recurrent and/or refractory multiple myeloma who have received treatment in the past and have received at least one proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody that is difficult to treat”. The 2023 edition of the National Health Insurance Catalogue will officially take effect on January 1, 2024.
SivioIt was approved for listing in China in December 2021. SivioIt is the world's first and only approved selective oral XPO1 inhibitor for nuclear export protein. Entering the 2023 edition of the National Health Insurance Catalogue this time will further enhance SivioAccessibility and affordability to meet the unmet medical needs of more patients with recurrent and/or refractory multiple myeloma.